Michael L Klein

Title: Michael L. Klein: Innovator in Antibody-Peptide Fusion Proteins

Introduction

Michael L. Klein is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-peptide fusion proteins for treating amyloid disorders. His innovative work has the potential to impact the treatment of various amyloid-based diseases.

Latest Patents

Michael L. Klein holds a patent for "Antibody-peptide fusion proteins for treating amyloid disorders." This patent describes antibody-peptide fusion proteins that comprise an amyloid-reactive peptide linked to an antibody. The methods outlined in the patent focus on treating amyloid-based diseases by administering these fusion proteins.

Career Highlights

Throughout his career, Klein has worked with notable organizations, including the University of Tennessee Research Foundation and Attralus, Inc. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Michael L. Klein has collaborated with esteemed colleagues such as Jonathan Wall and James S. Foster. These partnerships have fostered innovation and have been instrumental in the development of his research.

Conclusion

Michael L. Klein's work in antibody-peptide fusion proteins represents a significant advancement in the treatment of amyloid disorders. His contributions to biotechnology continue to pave the way for future innovations in the field.